#United States #Alzheimer's #Ellicott City #EvON Medics #Olfactory Therapy

EvON Medics Expands Horizons in Alzheimer's Treatment

EvON Medics, a frontrunner in the field of non-invasive neurotechnology, has made a significant advancement in combating Alzheimer's Disease. Recently, the company announced the publication of clinical data that validates its innovative treatment, known as Computerized Olfactory Adaptive Training (COAT). This transformative therapy could potentially redefine standard care practices for individuals experiencing Mild Cognitive Impairment (MCI).

Published in the prestigious journal Alzheimer's & Dementia: Translational Research & Clinical Interventions, the trial findings highlight a six-month randomized, double-blind, sham-controlled study, revealing that patients undergoing COAT experienced not only a reversal in gray matter loss but also a notable improvement in cognitive metrics, as evidenced by Preclinical Alzheimer's Cognitive Composite (PACC) score increases.

Clinical Trial Insights

The trial involved 70 participants diagnosed with MCI, divided into two groups: one receiving the COAT intervention and the other subjected to a placebo—essentially a single-odor sham method. Each participant underwent rigorous cognitive assessments and high-resolution MRI scans both before and after the intervention period. Results indicated that COAT participants achieved an impressive 2.34-point enhancement in PACC scores compared to the control group (p=0.02), a finding that remained significant even after covariate adjustments.

In addition to cognitive enhancements, a striking increase in gray matter volume (GMV) was documented in critical brain areas known to be affected in the early stages of Alzheimer's disease, specifically the entorhinal cortex (ERC) and hippocampus (HC). The precise measurements indicated that:

• - Right ERC: p=0.001
• - Left ERC: p=0.013
• - Right Hippocampus: p=0.034

These findings suggest a structural recovery process that holds profound implications for the treatment and understanding of Alzheimer's pathology.

Significance of Findings

The positive results from this study are potentially game-changing, as they not only emphasize the efficacy of a non-invasive, home-based cognitive training approach but also point toward new strategies for early intervention in Alzheimer's care. Charles Nwaokobia, President of EvON Medics, noted, "This study validates the potential of digital neurotherapeutics. We are not just alleviating Alzheimer's symptoms; we are addressing the foundational structural declines that accompany the disease."

Furthermore, Nwaokobia announced that an application for FDA Breakthrough Designation has been submitted, aiming to expedite the process for making this cutting-edge therapy available to the millions currently suffering from early-stage cognitive decline. The company’s newly launched application, ‘Memory Driver,’ presents an accessible platform for delivering this revolutionary therapy directly to users.

Expanding the Research

Evaristus Nwulia, Co-Founder and Chief Scientific Officer of EvON Medics, stated, “The entorhinal cortex is highly influential in the progression of early Alzheimer's. The observed volumetric increases in these regions are both unique and biologically significant.” While further pivotal trials are essential to confirm these findings, initial results consolidate the hypothesis that targeted olfactory engagement can revitalize neural networks, foster gray matter recovery, and subsequently lead to tangible cognitive improvements among patients with MCI.

The complete study is accessible for those interested at https://doi.org/10.1002/trc2.70226.

About EvON Medics

Founded in 2013, EvON Medics specializes in developing pioneering medical devices and digital therapeutic solutions explicitly designed for neurodegenerative conditions. By leveraging the latest advancements in neuroscience and digital health, the company is committed to enabling early detection and intervention strategies for Alzheimer's Disease and related ailments.

For further inquiries, please contact:
Charles Nwaokobia
President, EvON Medics LLC
Email: [email protected]
Phone: 914-888-7678